Matches in Wikidata for { <http://www.wikidata.org/entity/Q90671753> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q90671753 description "2019 թվականի հոկտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q90671753 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90671753 description "scientific article published on 10 October 2019" @default.
- Q90671753 description "wetenschappelijk artikel" @default.
- Q90671753 description "наукова стаття, опублікована 10 жовтня 2019" @default.
- Q90671753 name "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 name "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 type Item @default.
- Q90671753 label "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 label "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 prefLabel "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 prefLabel "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 P1433 Q90671753-89A6EDCB-273F-4E28-9501-65E20EEA4138 @default.
- Q90671753 P1476 Q90671753-8533B1C4-CA87-4DBE-9DEC-7B3037EE17A2 @default.
- Q90671753 P2093 Q90671753-A651AD6F-074C-4312-B7ED-A760E2A84AA5 @default.
- Q90671753 P304 Q90671753-918A1870-F3AE-442D-BF55-52100ABB158C @default.
- Q90671753 P31 Q90671753-262E1001-9872-41F1-86C0-4F730AF13E46 @default.
- Q90671753 P31 Q90671753-ebc161f5-760e-411b-892c-b11f1415b002 @default.
- Q90671753 P356 Q90671753-624B83A2-C7D3-4FD5-9825-9AC0AA470F1C @default.
- Q90671753 P433 Q90671753-6EB062F2-6697-4E80-8DEF-1E1D0A00465D @default.
- Q90671753 P478 Q90671753-11C8E247-4E26-4388-A319-0BEDF44E915A @default.
- Q90671753 P577 Q90671753-B11EB3F5-2656-4F73-BA5A-586DAE8DD99B @default.
- Q90671753 P698 Q90671753-0769F295-DF92-4850-9F20-47B005549428 @default.
- Q90671753 P356 J.GASTRO.2019.10.002 @default.
- Q90671753 P698 31606469 @default.
- Q90671753 P1433 Q4039279 @default.
- Q90671753 P1476 "Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?" @default.
- Q90671753 P2093 "Marc Bourliere" @default.
- Q90671753 P304 "1473-1475" @default.
- Q90671753 P31 Q13442814 @default.
- Q90671753 P31 Q871232 @default.
- Q90671753 P356 "10.1053/J.GASTRO.2019.10.002" @default.
- Q90671753 P433 "6" @default.
- Q90671753 P478 "157" @default.
- Q90671753 P577 "2019-10-10T00:00:00Z" @default.
- Q90671753 P698 "31606469" @default.